Literature DB >> 7833145

Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.

A R Hanauske1, H Depenbrock, D Shirvani, J Rastetter.   

Abstract

Epidermal growth factor (EGF) is a mitogenic peptide that binds to surface membrane receptors (EGFR) of breast cancer cells. After binding, secondary transmitter molecules are activated by tyrosine phosphorylation of the intracellular receptor domaine. The activity of the EGF/EGFR system can be modulated by a variety of chemically unrelated compounds including cytostatic agents. The purpose of our present study was to determine the effects of mitotic inhibitors on EGF receptor binding on human breast cancer cells. We found that MDA-231 and MDA-468 cells bind substantially more [125I]EGF after preincubation with docetaxel, vinblastine and vincristine. This effect was concentration- and time-dependent, reaching a maximum at 3000 ng/ml and 48 h incubation for docetaxel, and 100 ng/ml and 48 h incubation for vinca alcaloids. Subsequent experiments showed an increase in the rate of EGF binding as well as maximal binding capacity. Scatchard analysis of binding experiments under equilibrium conditions indicated that this was due to an increase in the number of apparent EGF binding sites. Modulation of EGF receptor binding by docetaxel, vinblastine, and vincristine was not detectable when isolated membranes were used, indicating that intact cytoplasmatic mechanisms are required for the upregulation of EGF receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7833145     DOI: 10.1016/0959-8049(94)00338-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Authors:  Hanna K Sanoff; Janine M Davies; Christine Walko; William Irvin; Larry Buie; Kimberly Keller; Anastasia Ivanova; Wing-Keung Chiu; Bert H O'Neil; Thomas E Stinchcombe; E Claire Dees
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

2.  Docetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution.

Authors:  Hong Zhang; Rui-ying Li; Xia Lu; Zhen-zhen Mou; Gui-mei Lin
Journal:  J Zhejiang Univ Sci B       Date:  2012-12       Impact factor: 3.066

3.  Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Authors:  Doris Posch; Hannah Fuchs; Gabriela Kornek; Anja Grah; Johannes Pammer; Marie-Bernadette Aretin; Thorsten Fuereder
Journal:  Sci Rep       Date:  2016-09-06       Impact factor: 4.379

4.  Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.

Authors:  Hannah Fuchs; Johannes Pammer; Christoph Minichsdorfer; Doris Posch; Gabriela Kornek; Marie-Bernadette Aretin; Thorsten Fuereder
Journal:  Med Oncol       Date:  2018-02-07       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.